跳至主要内容
临床试验/NCT00165542
NCT00165542已完成不适用

Determination of A-Protein Levels in Adult and Pediatric Brain Tumor Patients

Dana-Farber Cancer Institute1 个研究点 分布在 1 个国家目标入组 54 人开始时间: 1998年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
54
试验地点
1
主要终点
association between serum A-Protein level class and clinical status

研究概览

简要总结

The purpose of this study is to evaluate the sensitivity and specificity of "A-PROTEIN" levels in patients with brain tumors. A-PROTEIN levels will be analyzed both pre and post treatment. Levels in blood and/or cerebrospinal fluid (CSF) will be analyzed and correlated with the underlying diagnosis and outcome.

详细描述

  • Patients will be identified at the time of presentation to their neurologist, neurosurgeon or oncologist.
  • Blood or cerebrospinal fluid will be collected for this study only when they are being collected for other reasons before and after each surgery. Samples will also be collected after any event such as significant change in symptoms or radiographic progression.
  • Once the patients condition has been stabilized, samples will be take at regular intervals of >= 1 month. The duration of this study is 24 months.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
— 至 77 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All patients with possible malignant or benign lesions of the central nervous system will be included.
  • There are no restrictions with respect to treatment protocols or prior therapy.
  • Patients will be identified after presentation to the neurosurgical, neurological or oncologic services at participating centers. Any patient with evidence of a central nervous system tumor will be eligible. Individuals without evidence of CNS tumors are also eligible, in order to provide blinded controls.
  • A signed informed consent will be requested and required for participation.
  • There is no age, sex, or ethnic origin restrictions in this protocol. Patients who choose not to participate in the study will continue to have their regular care as defined by their treating team. Patients who speak foreign languages are eligible as long a translator can be found to ensure proper consent has been obtained.

排除标准

  • There are no exclusion criteria for this study.

结局指标

主要结局

association between serum A-Protein level class and clinical status

时间窗: 4 years

Serum samples were collected when patients were due for clinically indicated phlebotomy. Serum A-PROTEIN levels were determined using a competitive labeled antibody assay and patients were classified into 3 groups: negative \<7pM, equivocal 7-9.9 pM and positive \>/= 10 pM; Clinical status at the same time of the sample collection was established by MRI scans and patients grouped as either resected/decreased versus stable/increased. The relationship between clinical status and A-PROTEIN level was assessed using general estimating equations. Association was defined as a statistically significant p-value from the regression model.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mark W. Kieran, MD, PhD

Principal Investigator

Dana-Farber Cancer Institute

研究点 (1)

Loading locations...

相似试验

A-protein Levels in Adult and Pediatric Brain Tumor... | 临床试验